Skip to content
healthcare.dev

RANOLAZINE

NDC 68180-355, RANOLAZINE, tablet, film coated, extended release, from Lupin Pharmaceuticals, Inc..

Product NDC
68180-355
Status
Listed
Labeler
Lupin Pharmaceuticals, Inc.
Dosage form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Product type
HUMAN PRESCRIPTION DRUG
Marketing category
ANDA
Application
ANDA201046
DEA schedule
None
Request
curl https://api.healthcare.dev/v1/drugs/ndc/68180-355 \
  -H "Authorization: Bearer $HDEV_API_KEY"

Product

Active ingredients and packages

Active ingredients

  • RANOLAZINE1000 mg/1

Pharmacologic classes

Anti-anginal [EPC]; Cytochrome P450 2D6 Inhibitors [MoA]; Cytochrome P450 3A Inhibitors [MoA]; Organic Cation Transporter 2 Inhibitors [MoA]; P-Glycoprotein Inhibitors [MoA]

Package NDCNDC-11Package

Linked data

RxNorm, label and prices

RxNorm concepts

RxNorm links no concept to this product's packages.

Related lookups

  • FDA label sections

    GET /v1/drugs/labels/595821d7-1fbf-49a5-9c62-d78f27af39b4

Use it

Look up 68180-355 from code or an agent

curl
curl https://api.healthcare.dev/v1/drugs/ndc/68180-355 \
  -H "Authorization: Bearer $HDEV_API_KEY"
MCP prompt
Using the healthcare.dev MCP server, look up NDC 68180-355. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.

Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.